Upload
dr-anup-petare
View
182
Download
4
Embed Size (px)
Citation preview
03/05/2023 Dr Anup Petare. 1
Newer oral Anticoagulants
(NOACs)
DisclaimerAny views or opinions expressed in this presentation are solely those of the author and do not necessarily
represent those of company
03/05/2023 Dr Anup Petare. 2
Need of NOACs over Vitamin K antagonists
• Drug or food interactions
• Necessity of regular monitoring to adjust doses
• Slow onset
• Need for monitoring
• Narrow therapeutic window
• Polymorphism, Age, perioperative management
03/05/2023 Dr Anup Petare. 3
03/05/2023 Dr Anup Petare. 4
• Oral direct thrombin inhibitors(DTIs): Dabigatran
• Oral direct factor Xa inhibitors: Rivaroxaban, Apixaban, Edoxaban.
Classification of NOACs
03/05/2023 Dr Anup Petare. 5
Pharmacology of NOACsDabigatran Rivaroxaban Apixaban Edoxaban
Mechanism Direct thrombin inhibitor
Direct factor Xa inhibitor
Prodrug Yes NoBA 6% 66% NF
100% F50% 62%
Renal excretion
80% 35% 25% 50%
Liver metabolism
No Yes Minimal
GI tolerability
Dyspepsia -
Dosing BD OD BD OD
03/05/2023 Dr Anup Petare. 6
Dabigatran
• 1 st NOACs, (150mg) EMA & USFDA approved (RE-LY)
• (RE-LY) Primary efficacy endpoint (stroke and systemic embolism): Dabigatran 150 mg BID superior to warfarin with no significant differences in major bleedings.
• (Cf: warfarin) Reduced risk of ischaemic stroke, intracranial haemorrhage and mortality,
Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.Cardiovascular, bleeding, andmortality risks in elderlymedicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015;131:157–164.
03/05/2023 Dr Anup Petare. 7
Rivaroxaban
• Approved: USFDA and EMA (ROCKET AF)• non inferior to warfarin for the prevention of stroke or
systemic embolism• Black box warnings:
Premature discontinuation increases the risk of thrombotic events, Spinal/Epidural hematomas Monitor: S/S neurological impairment
03/05/2023 Dr Anup Petare. 8
Apixaban• (ARISTOTLE): significantly better than warfarin (overall
strokes—both ischaemic and haemorrhagic—and systemic emboli)• (AVERROES2): prematurely stopped = clear benefit in favour
of apixaban (Cf: Aspirin)
2. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–817.
1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTL Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.
03/05/2023 Dr Anup Petare. 9
Edoxaban• Edoxaban non-inferior to warfarin: Prevention of stroke or
systemic embolism (ENGAGE AF-TIMI);
03/05/2023 Dr Anup Petare. 10Wassef A, Butcher K. Novel oral anticoagulant management issues for the stroke clinician. Int J Stroke. 2016 Jul 27. pii: 1747493016660100.
03/05/2023 Dr Anup Petare. 11
Comparison between NOACs
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955–962.
03/05/2023 Dr Anup Petare. 12
03/05/2023 Dr Anup Petare. 13
High risk of stroke(high CHADS-VASC score)
Dabigatran 150 mg BID
Previous stroke Rivaroxaban 20 mg QDHigh risk of bleeding or previous
life-threatening bleedingsDabigatran 110 mg BID
Apixaban 5 mg BIDDyspepsia Rivaroxaban 20 mg QD
Apixaban 5 mg BID
GI bleeding Apixaban 5 mg BIDMedication compliance problems Rivaroxaban 20 mg QDElderly (≥80 years) and impaired
renal functionApixaban 2.5 mg BID
Choice of NOACs
03/05/2023 Dr Anup Petare. 14
Advantage of NOACs • Fixed-dosing
• Rapid onset
• No need for monitoring,
• Few interactions, no interaction with food
• Wider therapeutic window
03/05/2023 Dr Anup Petare. 15
Limitations of NOACs
• Lack of an effective antidote
• Cost
• Vitamin K Antagonists 1st line anticoagulant: Mechanical
heart valves or RHD and with severe renal insufficiency,
• ESC guidelines doesn’t recommend rivaroxaban and apixaban ( RHD, Mechanical heart valve, Severe renal insufficiency)
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385–1413.
1515
03/05/2023 Dr Anup Petare. 16
Conclusion• NOACs have a favourable balance between efficacy and
safety compared with VKAs• Individualized anticoagulant treatment: Age, RFT,
concomitant treatment• NOACs future depends upon clinical experience, patients’
tolerance to these drugs, novel data from further studies, reimbursement policies, and other market forces.• Further research is underway: Monitor anticoagulant effect,
antidote.